U.S. markets close in 33 minutes
  • S&P 500

    4,238.55
    -8.89 (-0.21%)
     
  • Dow 30

    34,263.09
    -216.51 (-0.63%)
     
  • Nasdaq

    14,120.98
    +51.55 (+0.37%)
     
  • Russell 2000

    2,320.92
    -14.88 (-0.64%)
     
  • Crude Oil

    70.91
    0.00 (0.00%)
     
  • Gold

    1,866.40
    -13.20 (-0.70%)
     
  • Silver

    28.01
    -0.14 (-0.48%)
     
  • EUR/USD

    1.2123
    +0.0016 (+0.13%)
     
  • 10-Yr Bond

    1.5010
    +0.0390 (+2.67%)
     
  • GBP/USD

    1.4110
    -0.0006 (-0.05%)
     
  • USD/JPY

    110.0820
    +0.4470 (+0.41%)
     
  • BTC-USD

    39,519.04
    +2,165.95 (+5.80%)
     
  • CMC Crypto 200

    988.08
    +19.24 (+1.99%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of patients who have failed estrogen blocking agents and CDK 4/6 inhibitors.

  • Data will be presented at the European Society for Medical Oncology Breast Cancer Virtual Congress 2021.

  • The subset of patients includes those who were heavily pretreated with estrogen-blocking agents and chemotherapy with an average of 3 prior lines of therapy in the metastatic setting and had tumor progression on a CDK 4/6 inhibitor before receiving enobosarm.

  • Enobosarm treatment in evaluable patients who had progressed following treatment with an estrogen-blocking agent and CDK 4/6 inhibitor (palbociclib) resulted in a clinical benefit rate at 24 weeks of 50% and a best objective tumor response of 30%, including two complete responses and one partial response.

  • The overall mean radiographic progression-free survival for the 9mg dose was ten months.

  • The 9mg dose of enobosarm was selected for the Phase 3 ARTEST study anticipated to start in June.

  • Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor, tumor suppressor, in AR+ER+HER2- metastatic breast cancer.

  • Price Action: VERU stock moved 26.4% higher at $11 during the premarket trading session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.